The company expects ZILRETTA (triamcinolone acetonide) sales this year of $65M - 80M.
Management will host a conference call tomorrow, January 4, at 8:30 am ET to discuss the results and outlook.
Shares are down 19% after hours in apparent reaction to its ZILRETTA outlook.
Now read: Merus reports Q3 results »
Subscribe for full text news in your inbox